BioCryst (BCRX) -41% after ending Phase III trials of its peramivir flu drug, as "the difference...

|About: BioCryst Pharmaceuticals,... (BCRX)|By:, SA News Editor

BioCryst (BCRX) -41% after ending Phase III trials of its peramivir flu drug, as "the difference between peramivir and control groups for the primary endpoint was small." BioCryst received $234.8M from the federal Biomedical Advanced Research & Development Authority to help develop peramivir. The setback follows BioCryst last week withdrawing its IND application for its BCX5191 hepatitis C compound. (PR)